The Phase III HALLMARQ study, which is expected to start by the end of the year, will evaluate overall survival in 350-400 patients who receive either Marquibo or standard vincristine
Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer demonstrated a 20.7 month median overall survival (OS) in a single-arm Phase II trial
Ltd., of Tokyo, reported Phase II results showing that its oral nucleoside cancer drug TAS-102 significantly improved overall survival compared to placebo (9 months vs. 6.6 months) and significantly reduced the risk of mortality (p = 0.0011) in patients with refractory metastatic colorectal cancer who had received standard chemotherapy of at least two or more regimens containing a fluoropyrimidine, irinotecan and oxaliplatin
The trial of 330 patients will evaluate overall survival with vaccination by IMA901 in combination with sunitinib (Sutent, Pfizer Inc.), in a general population of patients and in a subpopulation of patients positive for a biomarker signature associated with improved clinical outcome...Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported promising median overall survival of 12.4 months from a Phase II trial of bavituximab plus carboplatin and paclitaxel in metastatic non-small-cell lung
The open-label study will assess the efficacy of MORAb-004 at one of two doses as determined by progression-free survival in patients with metastatic melanoma in Australia, Europe and the U.S. Secondary objectives include assessment of an overall survival benefit and identification of biomarkers to predict efficacy
Median progression-free survival, overall survival and duration of response all were longer in the talactoferrin arm, though the differences were not statistically significant
CureTech Ltd., of Yavne, Israel, and Teva Pharmaceutical Industries Ltd., of Jerusalem, said CT-011 significantly improved progression-free survival (PFS) and overall survival (OS) in a Phase II trial for diffuse large B-cell lymphoma following autologous stem cell transplantation
The trial will enroll patients in their first complete remission who have received consolidation therapy, and will use overall survival as its endpoint
Millennium, of Cambridge, Mass., a unit of the Takeda Oncology Co., said results of a randomized Phase III trial that investigated the effect of consolidation with single-agent Velcade (bortezomib) for Injection in newly diagnosed multiple myeloma patients after autologous stem cell transplant showed significant improvements in response rates and progression-free survival, while the overall survival rate was 87 percent in both arms after a median follow-up of 27 months
At a median follow-up of 28 months, Revlimid maintenance significantly improved overall survival, with a rate of 90 percent for treated patients vs. 83 percent for placebo patients (p = 0.018, HR = 0.51...The study results gave median overall survival between 20 and 29 months
Merck Serono SA, a unit of Darmstadt, Germany-based Merck KGaA, said an updated analysis from the Phase III CRYSTAL trial found the addition of Erbitux (cetuximab) to standard chemotherapy in patients with KRAS wild-type disease resulted in significant improvement in overall survival of 3.5 months, compared to chemotherapy alone
The primary objective is to evaluate overall survival in the intent-to-treat population...Secondary endpoints include overall survival in the subpopulation of patients with epidermal growth factor receptor wild type, as well as progression-free survival and further assessment of the safety of the tivantinib/Tarceva combination
Based on overall survival data from the Phase IIb 003-A1 study, the company is changing the primary endpoint of the FOCUS trial from progression-free survival to overall survival
The Phase III HALLMARQ study, which is expected to start by the end of the year, will evaluate overall survival in 350-400 patients who receive either Marquibo or standard vincristine